LSTA: מכפיל P/S עתידי Lisata

Lisata Therapeutics (LSTA) is developing scalable solutions to combat solid tumors, aiming for a monopoly in the drug market. This chart on the GURU.Markets platform illustrates the business's forward P/S, which currently stands at 110.70. The model relies on CendR technology to enhance chemotherapy for pancreatic cancer. David Mazzo's team, backed by strong scientific expertise, is successfully advancing Phase II clinical trials.

Forward P/S measures an asset's market value relative to projected sales, making it possible to distinguish an undervalued asset from a stagnating business. The current value of 110.70 for the expected price-to-sales ratio reflects the scaling potential of the Lisata Therapeutics (LSTA) oncology drug delivery platform, helping investors assess the efficiency of commercial expansion and the risks of capital freeze while searching for a market bottom.